Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer (MIBC) | MicrobiomeTrials
Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer (MIBC)
RecruitingOBSERVATIONAL
Trial Details
Start: 2027-03Est. Completion: 2032-05
Enrollment target: 1,400 participants
Locations
UT Southwestern Medical Center, Dallas, Texas, United States